Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risperidone Depot (Microspheres) [Risperidone] in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-Label Follow-up Trial of RIS-INT-62 and RIS-INT-85.

Next Previous
Trial Profile

Risperidone Depot (Microspheres) [Risperidone] in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-Label Follow-up Trial of RIS-INT-62 and RIS-INT-85.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen

Most Recent Events

  • 21 May 2010 Actual patient number (314) added as reported by ClinicalTrials.gov.
  • 06 Feb 2008 Status changed from in progress to completed according to ClinicalTrials.gov
  • 19 Nov 2007 Status changed from completed to in progress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top